Interaction of Janus kinases JAK-1 and JAK-2 with the insulin receptor and the insulin-like growth factor-1 receptor
about
sameAs
Molecular basis of signaling specificity of insulin and IGF receptors: neglected corners and recent advancesInteraction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptorSignal transducer and activator of transcription (STAT)-induced STAT inhibitor 1 (SSI-1)/suppressor of cytokine signaling 1 (SOCS1) inhibits insulin signal transduction pathway through modulating insulin receptor substrate 1 (IRS-1) phosphorylationSustained recruitment of phospholipase C-gamma to Gab1 is required for HGF-induced branching tubulogenesisThe C terminus of c-Src inhibits breast tumor cell growth by a kinase-independent mechanism.The insulin receptor--a critical link in glucose homeostasis and insulin action.Regulation of Id gene expression by type I insulin-like growth factor: roles of Stat3 and the tyrosine 950 residue of the receptor.The mitogen-activated protein kinome from Anopheles gambiae: identification, phylogeny and functional characterization of the ERK, JNK and p38 MAP kinases.The aging lacrimal gland: changes in structure and function.Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulationInvited Review: Autocrine/paracrine IGF-I and skeletal muscle adaptation.Expression and effects of inhibition of type I insulin-like growth factor receptor tyrosine kinase in mantle cell lymphoma.Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulin therapy at reperfusion.A functional module-based exploration between inflammation and cancer in esophagus.Novel roles for insulin receptor (IR) in adipocytes and skeletal muscle cells via new and unexpected substrates.Abnormalities of IGF-I signaling in the pathogenesis of diseases of the bone, brain, and fetoplacental unit in humans.IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells.JAK-STAT signaling and myocardial glucose metabolism.Nuclearly translocated insulin-like growth factor 1 receptor phosphorylates histone H3 at tyrosine 41 and induces SNAI2 expression via Brg1 chromatin remodeling protein.Inputs and outputs of insulin receptor.JAKs go nuclear: emerging role of nuclear JAK1 and JAK2 in gene expression and cell growth.Role of the Janus kinase (JAK)/signal transducters and activators of transcription (STAT) cascade in advanced glycation end-product-induced cellular mitogenesis in NRK-49F cellsInhibition of the insulin-like growth factor system is a potential therapy for rheumatoid arthritis.Differentiation and mineralization of murine mesenchymal C3H10T1/2 cells in micromass culture.JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor.Janus kinase 2 modulates the apolipoprotein interactions with ABCA1 required for removing cellular cholesterol.Cell cycle-dependent interaction of Mad2 with conserved Box1/2 region of human granulocyte-macrophage colony-stimulating factor receptor common betac.Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase alpha (PI3Kalpha ). Functions of lipid kinase-deficient PI3Kalpha in signaling.Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway.Signalling pathways of insulin-like growth factor-I that are augmented by cAMP in FRTL-5 cells.Stimulation of pancreatic beta-cell proliferation by growth hormone is glucose-dependent: signal transduction via janus kinase 2 (JAK2)/signal transducer and activator of transcription 5 (STAT5) with no crosstalk to insulin receptor substrate-mediatType 3 Diabetes: Cross Talk between Differentially Regulated Proteins of Type 2 Diabetes Mellitus and Alzheimer's Disease.IGF-I downregulates resistin gene expression and protein secretion.Insulin induces suppressor of cytokine signaling-3 tyrosine phosphorylation through janus-activated kinase.Further evidence for the involvement of insulin receptor substrates in epidermal growth factor-induced activation of phosphatidylinositol 3-kinase.Effects of leukemia inhibitory factor on rat skeletal muscles are modulated by clenbuterol.Increased leptin and white adipose tissue hypoplasia are sexually dimorphic in Lif null/Igf-I haploinsufficient mice.The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.TRAF6 negatively regulates the Jak1-Erk pathway in interleukin-2 signaling.IGF-1-induced MMP-11 expression promotes the proliferation and invasion of gastric cancer cells through the JAK1/STAT3 signaling pathway.
P2860
Q21131281-AF5FFF67-2E04-4DAF-BF82-41583F5E217EQ21131281-C4FD706B-111F-4EDB-8B5D-AFF4EB9E82EFQ24310472-ECA8863D-919C-4658-AD86-0ACA8EFE6F6AQ24675835-8C21DF4E-31EE-48D2-ADE4-E6A02C686BF1Q24675835-C16A3842-DC5F-4C0B-ABFB-191607350683Q28139783-F5E8A335-7260-472D-9162-8F3AE1403E35Q30164215-BABDEC32-301C-4697-9473-8FBAC19E6DE1Q33599394-49B5928B-00D8-4588-9178-09D2A79B53FAQ33969194-5370AA4E-8441-4233-88B6-2A3C54DE55FDQ33969194-FB5F9A42-BA31-4DE9-AA40-CAA89E7B6A57Q34082049-13CB0F77-0B3E-4570-BDFD-7F2B94E2D08BQ34082049-306A9D9E-7512-43E6-A120-A504C55E2613Q34385610-35901FBF-7172-4CA8-A2CC-11026A95B828Q34385610-A160AD32-C5D9-4D63-B75F-D5EC28D7D5B2Q34387886-7E48D900-C30E-42D2-AC57-563081DEFD4CQ34387886-F8E32517-805D-4808-9A11-8D54E5C16EC5Q34787113-83057C59-B6FD-4FED-9013-ED4942A87453Q35018535-62C21504-D5CD-40F5-B16F-4CF90D4361DAQ35018535-B682D598-BB7E-4F80-A1D0-949E98EAB0D2Q36099739-39CC92F0-B9E7-457A-8C40-080125C0D3D5Q36099739-45E5D227-042A-49FD-947D-9EA58CA3F988Q36188784-13D3FBCF-4245-456A-B794-E810753AE61CQ36188784-5BD39C99-66CB-45D3-A248-83DFCD09BF6CQ36565904-1C740DBC-6325-4DF1-838B-DD8640105F8DQ36565904-9DCF9CD6-7360-430C-95B5-56F9931C77C7Q37247491-5BD62E7C-8C91-4507-A790-1B8FB7496B3EQ37271044-59CFB4EE-D921-42CB-B166-25A1E02A846EQ37271044-AF4F5258-4005-413F-9DD1-24314BCBA969Q37421817-8BA62C53-F8FC-49FB-A057-2901622D93C3Q37421817-D028EC41-75D7-4210-BCB8-984442684406Q37520529-57C5A427-84CD-4CCE-892A-9470A8866E70Q37520529-FDD9140D-FBB0-4E6E-99EA-A712D355D1A7Q37666434-A0D45868-4902-4317-9E6D-2B40B6FCDF5DQ37666434-B09EEB0F-FF70-4E35-949D-AA0B39B0C20AQ37926574-431A25CA-F885-4CB3-8FF2-82A90136D4DEQ37926574-F9CF2056-20A6-4240-B6C2-7348ED58175CQ38322138-81D3687D-B1B3-40E7-B49B-49401B811559Q38322138-BA379DB1-265C-486C-BA08-01CF8D14EB51Q38944284-BB000380-22E4-4C5E-9E6A-D16F698E6A99Q39720440-10E9FD90-6C80-4880-B641-3FB0B27D416B
P2860
Interaction of Janus kinases JAK-1 and JAK-2 with the insulin receptor and the insulin-like growth factor-1 receptor
description
1998 nî lūn-bûn
@nan
1998 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մարտին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
name
Interaction of Janus kinases J ...... -like growth factor-1 receptor
@ast
Interaction of Janus kinases J ...... -like growth factor-1 receptor
@en
Interaction of Janus kinases J ...... -like growth factor-1 receptor
@nl
type
label
Interaction of Janus kinases J ...... -like growth factor-1 receptor
@ast
Interaction of Janus kinases J ...... -like growth factor-1 receptor
@en
Interaction of Janus kinases J ...... -like growth factor-1 receptor
@nl
altLabel
Interaction of Janus Kinases J ...... Like Growth Factor-1 Receptor1
@en
Interaction of Janus Kinases J ...... Like Growth Factor-1 Receptor1
@nl
prefLabel
Interaction of Janus kinases J ...... -like growth factor-1 receptor
@ast
Interaction of Janus kinases J ...... -like growth factor-1 receptor
@en
Interaction of Janus kinases J ...... -like growth factor-1 receptor
@nl
P2093
P3181
P1433
P1476
Interaction of Janus Kinases J ...... Like Growth Factor-1 Receptor1
@en
Interaction of Janus kinases J ...... -like growth factor-1 receptor
@en
P2093
E Van Obberghen
Emmanuel Van Obberghen
Philippe Gual
Valérie Lequoy
Véronique Baron
P3181
P356
10.1210/EN.139.3.884
10.1210/ENDO.139.3.5829
P407
P577
1998-03-01T00:00:00Z